Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: oxazolidinone antibacterials - Durata

Drug Profile

Research programme: oxazolidinone antibacterials - Durata

Alternative Names: PF-00422602; PF-00708093; PF-02341752; PF-987296; VIC-104742; VIC-104988; VIC-105277; VIC-105491; VIC-105518; VIC-105535; VIC-105836; VIC-106632; VIC-106675; VIC-106699; VIC-106734; VIC-106814; VIC-106822; VIC-106828; VIC-106841; VIC-106857; VIC-106871; VIC-106922; VIC-106935; VIC-106936; VIC-106976; VIC-106993; VRC-104203; VRC-104766; VRC-104811; VRC-3783; VRC-4104; VRC-4203; VRC-4530; VRC-4766; VRC-4811

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacia Corporation; Vicuron Pharmaceuticals
  • Developer Pfizer
  • Class Oxazolidinones
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gram-positive infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-positive-infections in USA
  • 06 Oct 2014 Durata Therapeutics enters into a definitive merger agreement with Actavis
  • 15 Sep 2009 Preclinical trials in Gram-positive infections in USA (unspecified route)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top